

## Original Article

### Serum Vitamin D Level in Inflammatory Bowel Disease (IBD) and it's Association with IBD Activity

Miah MSA<sup>1</sup>, \*Chowdhury MFK<sup>2</sup>, Islam S<sup>3</sup>, Newaz AAS<sup>4</sup>, Akter D<sup>5</sup>, Saha T<sup>6</sup>, Akhter MT<sup>7</sup>, Adikhary D<sup>8</sup>, Saha KP<sup>9</sup>, Razib KO<sup>10</sup>, Ghosh CK<sup>11</sup>

#### Abstract

Vitamin D influences innate immunity, which is believed to be the imbalance of it involved in the pathogenesis of Inflammatory Bowel Disease (IBD). Evidence exists on the association between vitamin D deficiency and inflammatory bowel disease (IBD). To assess the serum vitamin D concentration in patients with inflammatory bowel disease and to study the relationship of vitamin D level with disease activity in the patients with inflammatory bowel disease. This case-control study was carried out in the department of Gastroenterology, Bangabandhu Sheikh Mujib Medical University (BSMMU). Total 40 IBD cases, diagnosed on clinical background and 40 apparently healthy control group of similar age and sex were taken. Blood samples were collected and serum vitamin D level was measured with Chemiluminescent Microparticle Immunoassay (CMIA) method in Biochemistry laboratory of BSMMU. The result were analyzed by statistical package for social sciences (SPSS) version 22. Vitamin D deficiency and insufficiency were defined as serum concentration of  $\leq 20$  ng/ml and 21–29 ng/ml respectively. Disease activity were evaluated using the Harvey Bradshaw Index for Crohn's Disease, Truelove and Witt's Index for Ulcerative colitis.

The vitamin D levels were correlated with disease activity in IBD patients comparing with control group. Mean ( $\pm$ SD) serum vitamin D levels were  $16.27 \pm 5.16$  ng/ml in IBD group and  $24.25 \pm 6.69$  in controls ( $p < 0.001$ ). Almost all (97 %) of IBD patients had low serum vitamin D in comparison to controls; more than three-fourth (77.5%) of the patients of IBD exhibited deficiency ( $< 20$  ng/ml), one-fifth (20%) had insufficiency (21–29 ng/ml) of serum vitamin D, whereas in the controls 30% had deficiency, 42.5% had insufficiency, and 27.5% had sufficient serum vitamin D. There was highly significant inverse correlation between vitamin D level and disease activity in IBD patients. The study showed that IBD patients had significantly lower serum vitamin D levels in comparison to controls. Serum vitamin D concentration is inversely correlated with disease activity in IBD patients. The study suggests that inadequate vitamin D level, along with other factors, probably contributes to the development of active disease in patients with IBD.

**Keywords:** Serum Vitamin D Level, IBD, crohn's disease, ulcerative colitis

#### INTRODUCTION

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD) is a chronic idiopathic inflammatory disorder of the gastrointestinal tract with a typically relapsing and remitting course<sup>27,46</sup>. Crohn's disease (CD) is a chronic inflammatory disorder that may involve any part of the alimentary tract from mouth to anus, with a propensity for the distal small intestine and proximal large bowel.<sup>10</sup>

UC is a chronic, relapsing disease characterized by diffuse mucosal inflammation of the colon.<sup>44</sup> It is thought to be caused by an inappropriate inflammatory response to the gut contents in genetically predisposed individuals.<sup>1</sup>

UC almost invariably involves the rectum and it may extend proximally in a continuous pattern to affect part of the colon or the entire colon. Clinical manifestations of active disease include bloody diarrhea (with or without mucus), urgency, tenesmus, abdominal pain, weight loss, fever, and malaise. Acute complications such as severe bleeding and toxic megacolon may occur, which can lead to perforation. There is an increased risk of colorectal cancer in UC patients. Risk factors include long duration of disease, extensive colonic involvement, severe inflammation and epithelial dysplasia, and childhood onset disease.<sup>17</sup>

Environmental factors such as smoking, medications such as non-steroidal anti-inflammatory drugs, stress and

1. Dr. Md. Shah Alam Miah, Assistant Registrar, Sheikh Russel National Gastroenterology Institute & Hospital, Mohakhali, Dhaka.
2. \*Dr. Md. Fazlul Karim Chowdhury, Assistant Professor, Department of Gastroenterology, Bangabandhu Sheikh Mujib Medical University. #01716330906. chanchal4234@gmail.com
3. Dr. Susmita Islam, Assistant Professor, Department of gastroenterology, BSMMU.
4. Dr. Abdullah Al Shah Newaz, Assistant Professor, Department of gastroenterology, BSMMU.
5. Dr. Dilruba Akter, Assistant Registrar, SRNGIH, Mohakhali, Dhaka.
6. Dr. Tanmoy Saha, Medical Officer, SRNGIH, Mohakhali, Dhaka.
7. Dr. Md. Tuhin Akhter, Registrar, SRNGIH, Mohakhali, Dhaka.
8. Dr. Debprosad Adikhary, Registrar (Medicine), Satkira Medical College Hospital, Satkira.
9. Dr. Kirshna Pada Saha, Assistant Professor, Department of Colorectal Surgery, BSMMU.
10. Dr. Kh. Olinor Razib, Medical Officer, Dept. of Neurosurgery, BSMMU.
11. Prof. Dr. Chanchal Kumar Ghosh, Professor Department of gastroenterology, BSMMU.

\*For correspondence

psychological factors such as depression, nutritional factors and even air pollution increase risk of IBD.<sup>2,3,4,5,50,65</sup>

Another environmental factor involved in the pathophysiology of IBD is vitamin D deficiency.<sup>47</sup> Vitamin D is a major regulator of calcium and phosphorus metabolism and key in maintaining bone health.<sup>50</sup> There is evidence that vitamin D plays a role in immune regulation.<sup>50</sup> Vitamin D receptors are expressed by immune cells, including antigen presenting cells, natural killer cells, B and T lymphocytes (Yap *et al.*, 2015).

Vitamin-D inhibit proliferation of T-helper cells and secretion of IL-2, IFN- $\gamma$  and IL-5, while increasing production of IL-4 by Th2 cells. Thus, vitamin D seems to modulate T-cell differentiation, driving cells towards the Th2 phenotype and inhibiting Th1 development.<sup>48</sup>

Recent studies support the role of vitamin D in the pathogenesis, clinical course, and also the potential treatment of autoimmune diseases such as multiple sclerosis<sup>51</sup>, systemic lupus erythematosus.<sup>40</sup> and IBD.<sup>51</sup> Vitamin D regulates epithelial cell integrity<sup>12,20,48</sup> and its deficiency leads to intestinal barrier dysfunction, mucosal damage, and susceptibility to infectious agents (Kong *et al.*, 2008, Assa *et al.*, 2014). It also affects the mucosal and systemic immune system activities, generally with regulatory and anti-inflammatory properties.<sup>667</sup> There is also evidence on the role of vitamin D on the gut microbiome, which is implicated in the pathogenesis and clinical course of IBD.<sup>12,20,48</sup> Accordingly, it is possible that vitamin D affects the severity of inflammation and disease course in IBD patients.<sup>50</sup>

## MATERIALS AND METHODS

This case control was carried out in the department of Gastroenterology, BSMMU, from November 2017 to February 2019. Adult patients with IBD diagnosed on the basis of compatible history, clinical features, laboratory findings and endoscopy with histopathology were enrolled in study group. Equal number of age-sex matched apparently healthy individuals selected from employees of the university or post graduate students those who voluntarily agreed and fulfilled the eligibility criteria was included as controls. We excluded patients with pregnancy, history of gastrointestinal surgery, female patients on hormonal contraception, chronic kidney

disease, diabetes mellitus, history of hypoparathyroidism, metastatic bone disease or other malignancies and patients taking vitamin D supplements that can be associated with vitamin D deficiency. Total eighty (80) participants, 40 were apparently healthy control and 40 patient fulfilling the inclusion criteria of inflammatory bowel disease (IBD), who were admitted or came for follow-up in IBD clinic in the Department of Gastroenterology at BSMMU were enrolled. Demographic and clinical characteristics were recorded. According to Harvey Bradshaw Index (HBI) for Disease Activity of Crohn's Disease patients were classified as Mild disease (5-7), Moderate disease (8-16), Severe disease (>16). Ulcerative colitis patients are classified as mild, moderate, severe by Truelove and Witts' severity index. Blood samples were purposively collected for serum Vitamin D in active disease group and age- gender matched healthy controls. Serum vitamin 25 (OH) D concentrations was measured with Architect ci 4100 using the Chemiluminescent microparticle immunoassay\* (CMIA) method In the Biochemistry Department of BSMMU.

Data were analyzed using SPSS version 22.0 software. Descriptive statics like frequency and corresponding percentage for qualitative data, mean and standard deviation for quantitative data were calculated. While the data presented on categorical scale were compared between groups using Chi-square (x<sup>2</sup>). The data presented on continuous scale were compared between groups with the help of unpaired t-Test. Quantitative data in three groups were compared by one way ANOVA test. P values of < 0.05 was considered significance.

## RESULTS

From November 2017 to February 2019 with 40 patients with diagnosis of crohn's disease or ulcerative colitis were consecutively enrolled as cases and 40 apparently healthy adult individuals as controls. Twenty of the IBD patients had CD and 20 had UC. Mean age of IBD patients was 32.10  $\pm$  9.99 years and 32.63  $\pm$  10 years of control group and age range was 18 - 60 years in both groups.

Table I states the distribution of the age in case and control groups; among the IBD patients 33 (82.5%) were in age group 17 -40 years and 7 (17.5%) were >40 years, whereas in the control 32 (80.0%) were in age group 17 -40 years and 8 (20.0%) were >40 years.

**Table-I: Distribution of the age in case and control (n=80)**

Age (years)	Case (n=40)	Control (n=40)	P value
17 - 40	33 (82.5)	32 (80.0)	
>40	7 (17.5)	8 (20.0)	
Mean±SD	32.10 ± 9.99	32.63 ± 10.00	0.815

Unpaired t test was done to measure the level of significance

Table II shows the distribution of the sex in case and control groups; among the IBD patients 25 (62.5%) were males and 15 (37.5%) were females, whereas in the control 25 (62.5%) were males and 15 (37.5%) were females.

**Table-II: Distribution of the sex in case and control groups (n=80)**

Gender	Case (n=40)	Control (n=40)	p-value
Male	25 (62.5)	25 (62.5)	1.000
Female	15 (37.5)	15 (37.5)	

Chi-square test was done to measure the level of significance

Table III states the distribution of vitamin D level both in case and control groups; In IBD patients 31 (77.5%) had deficiency, 8 (20%) had insufficiency, and 1 (2.5%) had sufficiency of serum vitamin D level, whereas in the control group, 12 (30%) had deficiency, 17 (42.5 %) had insufficiency, and 11 (27.5%) sufficiency in serum vitamin D level. IBD patients had significantly lower mean serum level of vitamin D as compared to the control group (16.27± 5.16 vs. 24.25 ±6.69) respectively and P value <0.001).

**Table- III: Distribution of vitamin D level in case and control groups (n=80)**

Vitamin D	Case (n=40)	Control (n=40)	p-value
≤20 (Vit-D deficiency)	31 (77.5)	12 (30.0)	21-29
(Vit-D insufficiency)	8 (20.0)	17 (42.5)	
>29-100 (Sufficient Vit-D)	1 (2.5)	11 (27.5)	<0.001
Mean±SD	16.27±5.16	24.25±6.69	

Unpaired t test was done to measure the level of significance

Table IV contains the distribution of the duration of illness of the IBD patients; here duration of illness of 24 (60%) patients were > 4 weeks (established case), 16 (40%) were ≤ 4 weeks (new case) duration.

**Table -IV: Duration of illness of the IBD Patients (n=40)**

Duration of illness (months)	Frequency (n)	Percentage (%)
≤4 weeks	16	40.0
>4 weeks	24	60.0
Mean±SD (years)	2.45 ±3.73 (0.08 - 20)	

Table V shows the distribution of type of IBD and its severity. Here both Cron's disease and ulcerative colitis was equal in number (50%).

**Table -V : Type of IBD and its severity (n=40)**

Severity of disease	Crohn's disease (n=20)	Ulcerative colitis (n=20)	Total
Mild	4 (20.0)	5 (25.0)	9 (22.5)
Moderate	6 (30.0)	5 (25.0)	11 (27.5)
Severe	10 (50.0)	10 (50.0)	20 (50.0)

Table VI shows the comparison of lab parameters between Crohn's disease and Ulcerative colitis. No significant difference of vitamin D level, Hb%, ESR and CRP were found between Crohn's disease and Ulcerative colitis patients (15.50 ± 4.26 vs 17.05 ± 5.94, p=0.349), (11.25 ± 2.84 vs 11.65 ± 2.66, p=0.649), (26.80 ± 17.01 vs 43.00 ± 30.64, p=0.046) and (26.85 ± 37.18 vs 24.10 ± 34.70, p=0.810) respectively.

**Table- VI: Comparison of lab parameters between Crohn's disease and Ulcerative colitis (n=40)**

	Crohn's disease (n=20)	Ulcerative colitis (n=20)	p-value
25(OH)D level	15.50±4.26	17.05±5.94	0.349
Hb%	11.25±2.84	11.65±2.66	0.649
ESR	26.80±17.01	43.00±30.64	0.046
CRP	26.85±37.18	24.10±34.70	0.810

Unpaired t test was done to measure the level of significance

Table VII shows the 25(OH)D level according to severity of IBD; as Crohn’s Disease activity increased, the level of serum vitamin D decreased (21.0 ±1.41 , 17.17±22.93, 12.30±2.50) reciprocally and P value <0.001. Also as the disease activity of Ulcerative colitis increased, the level of Vitamin D decreased (25.0 ±3.08, 17.40±1.67, 12.90± 3.84) reciprocally and P value <0.001.

**Table -VII: 25(OH)D level according to severity of IBD (n=40)**

Type of IBD	Mild (n=20)	Moderate (n=20)	Severe	Total
Crohn’s disease (n=20)	21.00 ± 1.41	17.17 ± 2.93	12.30 ± 2.50	<0.001
Ulcerative colitis (n=20)	25.00 ± 3.08	7.40 ± 11.67	12.90 ± 3.84	<0.001
Total	23.22 ± 3.15	17.27 ± 2.33	12.60 ± 3.17	<0.001

ANOVA test was done to measure the level of significance

Table VIII shows the 25(OH)D level according to duration of IBD; here, no difference of Vitamin D was found between newly diagnosed patients with established cases both in CD group (17.33 ± 4.12 ng/mL vs 14.00 ± 3.92, p value 0.081) and UC group (16.57 ± 5.96 vs 17.30 ± 6.15, p value 0.80) .

**Table- VIII: 25(OH)D level according to duration of IBD (n=40)**

Type of IBD	< 1 months (n=20)	≥ 1 months (n=20)	Total
Crohn’s disease (n=20)			
<20	8 (88.9)	10 (90.9)	
21 - 29	1 (11.1)	1 (9.1)	
Mean±SD	17.33 ± 4.12	14.00 ± 3.92	0.081
Ulcerative colitis (n=20)			
<20	5 (71.4)	9 (69.2)	
21 - 29	2 (28.6)	3 (23.1)	
30 - 100	0 (0.0)	1 (7.7)	
Mean±SD	16.57 ± 5.96	17.30 ± 6.15	0.800

Unpaired t test was done to measure the level of significance

Table IX illustrate the distribution of serum Vitamin D level among IBD and controls by age; here in male 10 (40%) had insufficiency, 9(36%) had sufficiency and 6(24%) had deficiency of serum vitamin D level. IBD patients had significantly lower serum vitamin D level as compared to the control group (16.27± 5.16 vs. 24.25 ± 6.69, P value <0.001). The difference was significant.

[In IBD patients 13(86.66%) had deficiency, 1(6.66%) had insufficiency and 1(6.66%) had sufficiency of serum vitamin D level].

**Table-IX: Distribution of IBD and controls by age (n=80)**

Age	Deficiency (≤20)	Insufficiency (21 – 29)	Sufficiency (>29)	p-value
IBD				
17 – 40	26 (81.3)	6 (85.7)	1 (100.0)	0.862
>40	6 (18.8)	1 (14.3)	0 (0.0)	
Control				
17 – 40	8 (66.7)	16 (94.1)	8 (72.7)	0.148
>40	4 (33.3)	1 (5.9)	3 (27.3)	

Chi-square test was done to measure the level of significance

Table X states the distribution of serum Vitamin D level among IBD and controls by sex; in male 19 (76%) had deficiency, 6(24%) had insufficiency of serum vitamin D level. In the healthy control females, 7 (46.66%) had insufficiency, 6(40%) had deficiency and 2 (13.33%) had insufficiency in serum vitamin D level.

**Table-X: Distribution of IBD and controls by gender (n=80)**

Gender	Deficiency (≤20)	Insufficiency (21 – 29)	Sufficiency (>29)	p-value
IBD				
Male	19 (59.4)	6 (85.7)	0 (0.0)	0.182
Female	13 (40.6)	1 (14.3)	1 (100.0)	
Control				
Male	6 (50.0)	10 (58.8)	9 (81.8)	0.266
Female	6 (50.0)	7 (41.2)	2 (18.2)	

Table XI illustrate the distribution of Crohn’s disease severity and Vitamin D status; in Crohn’s disease patients, half 10 (50%) had severe disease activity (>16), followed by 6 (30%) moderate disease activity (8-16) and 4 (20%) mild disease activity (5-7).

**Table-XI: Distribution of Crohn’s disease severity and Vitamin D status (n=20)**

Level of 25 (OH)D	Mild (n=4)	Moderate (n=6)	Severe (n=10)	Total
<20	2 (50.0)	6 (100.0)	10 (100.0)	
21 - 29	2 (50.0)	0 (0.0)	0 (0.0)	
Mean±SD	21.00±1.41	17.17±2.93	12.30±2.50	<0.001

ANOVA test was done to measure the level of significance

Table XII illustrate the distribution of ulcerative colitis severity and Vitamin D status; in ulcerative colitis patients, half 10 (50%) had severe disease activity, followed by 5(25%) moderate disease activity and 5 (25%) mild disease activity.

**Table-XII: Distribution of Ulcerative colitis severity and Vitamin D status (n=20)**

Level of 25 (OH)D	Mild (n=5)	Moderate (n=5)	Severe (n=10)	Total
<20	0 (0.0)	5 (100.0)	9 (90.0)	
21 - 29	4 (80.0)	0 (0.0)	1 (10.0)	
30 - 100	1 (20.0)	0 (0.0)	0 (0.0)	
Mean±SD	25.00±3.08	17.40±1.67	12.90±3.84	<0.001

ANOVA test was done to measure the level of significance

Table XIII shows the distribution of IBD by ESR and vitamin D; there were statistically significant association between vitamin D levels and erythrocyte sedimentation rate (36.31 ± 27.63 vs 26.29 ± 15.70 vs 50.00 ± 0.00 , p value <0.001).

**Table-XIII: Distribution of IBD by ESR and vitamin D (n=40)**

ESR	Deficiency (≤20) (n=32)	Insufficiency (21 - 29) (n=7)	Sufficiency (>29) (n=1)	p-value
>30	15 (46.9)	2 (28.6)	1 (100.0)	
≤30	17 (53.1)	5 (71.4)	0 (0.0)	
Total	36.31±27.63	26.29±15.70	50.00±0.00	<0.001

ANOVA test was done to measure the level of significance

Table XIV shows the distribution of IBD by CPR and vitamin D; there were statistically significant association between vitamin D levels and serum C-reactive protein (27.88 ± 35.28 vs 18.00 ± 39.73 vs 1.00 ± 0.00, p vale <0.001).

**Table-XIV: Distribution of IBD by CRP and vitamin D (n=40)**

CRP	Deficiency (≤20) (n=32)	Insufficiency (21 - 29) (n=7)	Sufficiency (>29) (n=1)	p-value
>6	26 (81.3)	2 (28.6)	0 (0.0)	
≤6	6 (18.8)	5 (71.4)	1 (100.0)	
Total	27.88±35.28	18.00±39.73	1.00±0.00	<0.001

ANOVA test was done to measure the level of significance

## DISCUSSION

In recent years, vitamin D has attracted a significant amount of scientific attention (Bruyn et al., 2013). Along with function of regulating the phosphocalcic metabolism, growing evidence point its anti-inflammatory, anti-proliferative and anti-apoptotic functions.<sup>63</sup> It is estimated that as many as one billion people worldwide suffer from vitamin D deficiency or insufficiency and this was shown to be prevalent across all age groups, genders, and geographic regions.<sup>19,31,32</sup> So, it is important to emphasize that vitamin D deficiency is a current public health issue that has been increasing, including in healthy individuals of all ages in developed and developing countries.

The present case-control study was carried out with the aim to determine the prevalence of vitamin D concentration in Inflammatory Bowel Disease and to compare them with that of apparently healthy controls and correlate with disease activity of IBD patients.<sup>28</sup>

The present study included forty inflammatory bowel disease (IBD) patients (15 females and 25 males) and forty (age and sex matched) healthy control participants. In this study we have seen significantly lower mean serum vitamin D levels in IBD patients compared to controls, (16.27±5.16 ng/ml) vs (24.25±6.69 ng/ml) respectively with p value<0.001. These finding are consistent with research finding of<sup>21</sup> who reported mean vitamin D levels in IBD patients was 24±10 ng/ml and in controls 31±13 ng/ml. The difference was significant, *p*<0.05.

When IBD patients and control subjects were classified according to Vitamin D status, among 40 IBD cases, 39 cases (97.5%) had low vitamin D concentration (<30 ng/ml); only one case (2.5%) had sufficient vitamin D concentration ( $\geq 30$  ng/ml). Out of 39 low vitamin D patients, 31 cases (77.5%) were deficient ( $\leq 20$  ng/ml) and 8 cases (20.0%) were insufficient (21-29 ng/ml). Among 40 control subjects, 29 participants (72.5%) were found to be low vitamin D (<30ng/ml) while in 11 participants (27.5%) vitamin D level were sufficient. This means that vitamin D deficiency is more prevalent in IBD patients than control subjects.

In the present study, however 1 out of 40 IBD patients and 11 out of 40 control subjects had sufficient vitamin D concentration. This was also similar with result of with results of <sup>63,22</sup> who confirmed lower levels of vitamin D among IBD patients as compared to the controls. The result of this study, however dissimilar with results of Ko *et al.*,(2019) who found that there was no significant difference in vitamin D levels between groups. This may be due to demographics, physical activity, and nutritional status.

In our study no difference was found in the prevalence of low vitamin D between CD and UC patients. This agrees with the results of study by <sup>39,22</sup> However this study result do not agree with the result of <sup>63</sup> They reported that mean 25(OH)D levels were lower in CD patients compared with UC patients.

In the present study, as regard to age, there was no significant difference between IBD patients with different vitamin D status (Vitamin D deficiency and Vitamin D insufficiency). This finding is similar with the finding of <sup>56</sup> However, the results of this present study did not agree with results of <sup>62</sup> who reported younger patient were more Vitamin D deficient.

In our study there was no significant difference between IBD patients with different vitamin D status (vitamin D deficiency and vitamin D insufficiency) as regard to gender with p value = 0.182. Our observations are consistent with the findings of Hassan *et al.*,(2013) . However, the results of our study did not agree with results of <sup>39,68</sup> who reported the prevalence of low vitamin D was higher in males.

In the present study there was no significant difference between vitamin D level and disease duration (new case vs established case, p value 0.081). This however, did not agrees with the result of study by <sup>63</sup> who reported more

vitamin D deficiency in patients with longer disease duration and <sup>21</sup> who reported newly diagnosed IBD patients had lower Vitamin D levels than established cases.

In our study there was a significant difference between different vitamin D status (vitamin D deficiency and insufficiency) as regard to HBI in Crohn's disease and Truelove and Witt's severity in Ulcerative colitis. It was also found that vitamin D correlated inversely with IBD disease activity. These findings are similar with study by <sup>68</sup> who also reported the association between higher disease activity and lower vitamin D levels. <sup>9</sup> reported vitamin D levels decreased with increased disease activity in ulcerative colitis patients. <sup>9,21,38</sup> reported significant correlation between vitamin D levels and crohn's disease activity but no significant correlation with ulcerative colitis disease activity. However <sup>22</sup> reported that serum vitamin D levels are not affected by disease severity in IBD patients (both UC and CD patients).

## CONCLUSION

In this case-control study, we observed that average serum vitamin D concentration of IBD patients were significantly low in comparison to controls. In our study, vitamin D concentration inversely correlated with disease activity and not significantly correlated with age and disease duration. The study suggests that inadequate vitamin D level, along with other factors, probably contributes to the development of active disease in patients with IBD.

## Limitation

Only a small number of IBD patients and controls were enrolled. The participants were from one centre, so result can't be generalized to reference population. Dietary intake of vitamin D, nutritional status of study participants not studied. Seasonal variation, time spent in sunlight were not studied.

## Recommendation

Further large scale studies should be considered to strengthen the study and establish the relationship of vitamin D levels with IBD along with other cofounders.

## REFERENCES

1. Abraham C, Cho JH. Inflammatory bowel disease. *N Engl J Med.* 2009;361(21):2066-78. Alkhoury RH, Hashmi H, Baker RD, Gelfond D, Baker SS. Vitamin and mineral status in patients with inflammatory

- bowel disease. *J Pediatr Gastroenterol Nutr* 2013; 56: 89–92.
2. Ananthakrishnan AN, Cagan A, Gainer VS, et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. *Inflamm Bowel Dis* 2013; 19: 1921–7.
  3. Ananthakrishnan AN. Environmental risk factors for inflammatory bowel diseases: a review. *Dig Dis Sci*. 2015;60:290–298
  4. Ananthakrishnan AN, Cheng SC, Cai T, et al. Association between reduced plasma 25-hydroxy vitamin D and increased risk of cancer in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol*
  5. Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. *Gastroenterology*. 2012;30. Logan I, Bowlus CL. The geoepidemiology of autoimmune intestinal diseases. *Autoimmun Rev*. 2010;9:A372–A378
  6. Aronson, R.A., Cook, S.L. and Roche, J.K. (1983) 'Sensitization to epithelial antigens in chronic mucosal inflammatory disease. I. Purification, characterization, and immune reactivity of murine epithelial cell-associated components (ECAC). *The Journal of Immunology*, 131(6), pp.2796-2804.
  7. Aufses, AH. (2001) 'The history of Crohn's disease', *Surg Clin North Am*, 81, pp. 1-11.
  8. Barnich, N., Carvalho, F., Glasser, A. et al. (2007) 'CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease' *J Clin Invest*, 117, pp. 1566-74.
  9. Blanck S, Abera F. Vitamin d deficiency is associated with ulcerative colitis disease activity. *Dig Dis Sci*. 2013;36. Jorgensen SP, Hvas CL, Agnholt J, Christensen
  10. Bruce E. Sands and Corey A. Siegel. (2016) 'Crohn's Disease.' In Feldman M., Friedman LS and Brandt, Lawrence J., eds. *Sleisenger and Fordtran's Gastrointestinal and Liver disease*. 10th ed. Elsevier Saunders, pp.1990-2021.
  11. Brzezinski, A. (2011) ' Medical management of the patient with an ostomy. In: Lichtenstein GR, Scherl EJ, editors. *Crohn's Disease: the Complete Guide to Medical Management*, NJ: Thorofare, pp. 417-423.
  12. Cantorna MT, McDaniel K, Bora S, Chen J, James J. Vitamin D, immune regulation, the microbiota, and inflammatory bowel disease. *ExpBiol Med* (Maywood) 2014
  13. Cho JH, Brant SR. (2011) 'Recent insights into the genetics of inflammatory bowel disease' *Gastroenterology*, 140, pp. 1704-12.
  14. Crohn, BB, Ginzburg, L, Oppenheimer, GD. (1932) 'Regional ileitis: a pathological and clinical entity' *JAMA*, 99, pp. 1323-29.
  15. Crohn BB, Ginzburg L, Oppenheimer GD. (1952) Regional ileitis. 'A pathologic and clinical entity' *The American Journal of Medicine*, 13 (5), pp. 583-590.
  16. Cosnes, J., Gower-Rousseau, C., Seksik, P. et al. (2011) 'Epidemiology and natural history of inflammatory bowel diseases', *Gastroenterology*, 140, pp. 1785-94
  17. Danese S. and Fiocchi C. (2011) 'Ulcerative Colitis.' *N Engl J Med*, 365(18) pp. 1713-1725.
  18. Daniel J. Mulder, Angela J. Nobl, Christopher J. Justinich, Jacalyn M. Duffin, A tale of two diseases: The history of inflammatory bowel disease, *journal of Crohn's and Colitis*, 2014;341-348.
  19. Dawson-Hughes, B, Heaney, RP, Holick, MF, Lips, P, Meunier, PJ, Reinhold Vieth, R 2005, 'Estimates of optimal vitamin D status', *International Osteoporosis Foundation*, vol.10, pp.1867-1877.
  20. Deluca, H.F. and Cantorna, M.T., 2001. Vitamin D: its role and uses in immunology. *The FASEB Journal*, 15(14), pp.2579-2585.
  21. Dumitrescu G, Mihai C, Dranga M, Prelipcean CC. Serum 25-hydroxyvitamin D concentration and inflammatory bowel disease characteristics in Romania. *World J Gastroenterol*. 2014;20(9):2392-6.
  22. El-Matary W, Sikora S, Spady D. Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. *Dig Dis Sci* 2011; 56: 825–9
  23. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. *Am J Public Health*. 2006;96:252–261
  24. Feldman, M., Friedman, S., and Brandt, J. (2016) *Sleisenger and Fordtran's gastrointestinal and liver disease*. Philadelphia: Elsevier Saunders.

25. Ham M, Longhi MS, Lahiff C, Cheifetz A, Robson S, Moss AC. Vitamin D levels in adults with Crohn's disease are responsive to disease activity and treatment. *Inflamm Bowel Dis*. 2014;20:856–860
26. Hamann, A., Andrew, D.P., Jablonski-Westrich, D., Holzmann, B. and Butcher, E.C. (1994) Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo. *The Journal of Immunology*, 152(7), pp.3282-3293.
27. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. *Inflamm Bowel Dis*. 2006;12:S3–S9
28. Harvey FR, Bradshaw JM. A simple index of Crohn's disease activity. *Lancet* 1980;1:514.
29. Hassan V, Hassan S, Seyed-Javad P, Ahmad K, Asieh H, Maryam S, Farid F, Siavash A. Association between Serum 25 (OH) Vitamin D Concentrations and Inflammatory Bowel Diseases (IBDs) Activity. *Med J Malaysia* 2013; 68: 34-38
30. Heickendorff L, Dahlerup JF. Active Crohn's disease is associated with low vitamin D levels. *J Crohns Colitis*. 2013
31. Holick, M.F., 2007. Vitamin D deficiency. *New England Journal of Medicine*, 357(3)pp.266-281.
32. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *Clin Endocrinol Metab* .2011
33. Islam MZ, Lamberg-Allardt C, Kärkkäinen M, Outila T, Salamatullah Q, Shamim AA. Vitamin D deficiency: a concern in premenopausal Bangladeshi women of two socio-economic groups in rural and urban region. *Eur J Clin Nutr* 2002; 56: 51-56.
34. Islam, Q.T. and Amin, M.R., 2017. Hypovitaminosis D in Adult-A systemic Review. *Bangladesh Journal of Medicine*, 28(1), pp.34-40.
35. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. *Scand J Gastroenterol* 2002; 37: 192-199
36. Jorgensen SP, Hvas CL, Agnholt J, Christensen LA, Heickendorff L, Dahlerup JF. Active Crohn's disease is associated with low vitamin D levels. *J Crohns Colitis*. 2013;7:e407–e413
37. Joseph AJ, George B, Pulimood AB, Seshadri MS, Chacko A. 25(OH) vitamin D level in Crohn's disease: association with sun exposure & disease activity. *Indian J Med Res* 2009; 130: 133–7.
38. Jussila A, Virta LJ, Salomaa V, Maki J, Jula A, Farkkila MA. High and increasing prevalence of inflammatory bowel disease in Finland with a clear North-South difference. *J Crohns Colitis*. 2013
39. Kabbani, T.A., Koutroubakis, I.E., Schoen, R.E., Ramos-Rivers, C., Shah, N.A., Swoger, J.M., Regueiro, M.D., Barrie, A.M., Schwartz, M.B., Hashash, J.G., Baidoo, L., Dunn, M.A., & Binion, D.G. (2016). Association of Vitamin D Level With Clinical Status in Inflammatory Bowel Disease: A 5-Year Longitudinal Study. *The American Journal of Gastroenterology*, 111, 712-719.
40. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. *Autoimmun Rev*. 2006;5:114–117
41. Ko KH, Kim YS, Lee BK, et al. Vitamin D deficiency is associated with disease activity in patients with Crohn's disease. *Intest Res*. 2018;17(1):70-77.
42. Koivula MK, Matinlassi N, Laitinen P, Risteli J. Four automated 25-OH total vitamin D immunoassays and commercial liquid chromatography tandem-mass spectrometry in Finnish population. *Clin Lab* 2013; 59: 397–405
43. Kuwabara A, Tanaka K, Tsugawa N, et al. High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. *Osteoporos Int* 2009; 20: 935–42
44. Langan, R.C., Gotsch, P.B., Krafczyk, M.A. and Skillinge, D.D. (2007) 'Ulcerative colitis: diagnosis and treatment.' *American family physician*, 76(9).
45. Levin AD, Wadhera V, Leach ST, Woodhead HJ, Lemberg DA, MendozaCruz AC, et al. Vitamin D deficiency in children with inflammatory bowel disease. *Dig Dis Sci*. 2011;56:830–6.
46. Lim WC, Hanauer SB, Li YC. Mechanisms of disease: vitamin D and inflammatory bowel disease. *Nat ClinPractGastroenterol Hepatol*.2005;2:308–315.
47. Mark T, Osterman and Gary R, Lichtensten. (2016) 'UlcerativeColitis.' In Feldman, L.S and Brandt, L.J.,



- eds. Sleisenger and Fordtran's Gastrointestinal and Liver disease. 10th ed. India: Elsevier Saunders, pp. 2023-2061
48. Mahon, B.D., Wittke, A., Weaver, V., Cantorna, M.T., 2003. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. *J. Cell Biochem.* 89, 922–932.
  49. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. *Nat Rev Immunol* 2008;8:685–698.
  50. Mouli VP, Ananthkrishnan AN. Review article: vitamin D and inflammatory bowel diseases. *Aliment Pharmacol Ther.* 2014;39:125–136.
  51. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. *Neurology.* 2004;62:60–65
  52. Naderi N, Farnood A, Habibi M, et al. Association of vitamin D receptor gene polymorphisms in Iranian patients with inflammatory bowel disease. *J Gastroenterol Hepatol.* 2008
  53. Naser, SA, Ghobrial, G, Romero, C, Valentine, JF. (2004) 'Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease', *Lancet*, 364, pp. 1039-44.
  54. Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, Wong TC, Leung VK, Tsang SW, Yu HH and Li MF. (2013) 'Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study.' *Gastroenterology*, 145(1), pp.158-165.
  55. Raedler, A., Fraenkel, S., Klose, G. et al. (1985) 'Elevated numbers of peripheral T cells in inflammatory bowel diseases displaying T9 antigen and Fc alpha receptors' *Clin Exp Immunol*, 60, pp. 518-24.
  56. Raftery T, Merrick M, Healy M, et al. Vitamin D status is associated with intestinal inflammation as measured by fecal calprotectin in Crohn's disease in clinical remission
  57. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. *Gut.* 2006;55(6):749-53.
  58. Sheikh, A., Saeed, Z., Jafri, S.A.D., Yazdani, I. and Hussain, S.A., 2012. Vitamin D levels in asymptomatic adults—a population survey in Karachi, Pakistan. *PLoS One*, 7(3), p.e33452.
  59. Shih, D.Q. and Targan, S.R. (2008) 'Immunopathogenesis of inflammatory bowel disease.' *World journal of gastroenterology: WJG*, 14(3), pp.390.
  60. Siffledeen JS, Siminoski K, Steinhart H, Greenberg G, Fedorak RN. The frequency of vitamin D deficiency in adults with Crohn's disease. *Can J Gastroenterol* 2003; 17: 473-47
  61. Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. *J Intern Med* 1996; 239: 131-137
  62. Torki M, Gholamrezaei A, Mirbagher L, Danesh M, Kheiri S, Emami MH. Vitamin D deficiency associated with disease activity in patients with inflammatory bowel diseases. *Dig Dis Sci* 2015;60: 3085-3091.
  63. Torella MC, Rausch A, Lasa J, Zubiaurre I. Vitamin D deficiency among inflammatory bowel disease patients in Argentina: a cross-sectional study. *Arq. Gastroenterol* 2018; 55, 3, 216-220
  64. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. *Br Med J.* 1955;2(4947):1041-8.
  65. Ulitsky A, Ananthkrishnan AN, Naik A, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. *JPEN J Parenter Enteral Nutr* 2011;35: 308-316.
  66. Van Etten E, Mathieu C 2005 Immunoregulation by 1,25-dihydroxyvitamin D<sub>3</sub>: basic concepts. *J Steroid Biochem Mol Biol* 97:93–101
  67. Xue LN, Xu KQ, Zhang W, Wang Q, Wu J, Wang XY. Associations between vitamin D receptor polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a metaanalysis. *Inflamm Bowel Dis.* 2013 28.
  68. Zammit CS, Ellul P, Girardin G, et al. Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study. *Eur J Gastroenterol Hepatol* 2018;30:1297–303.